Yiannopoulou Konstantina G, Anastasiou Aikaterini I, Kontoangelos Konstantinos, Papageorgiou Charalambos, Anastasiou Ioannis P
Department of Neurology, "Henry Dunant" Hospital Center, Athens, Greece.
Medical School of Athens, National and Kapodistrian University of Athens, Athens, Greece.
Curr Urol. 2020 Dec;14(4):169-177. doi: 10.1159/000499242. Epub 2020 Dec 18.
Psychological morbidity as well as cognitive impairment are increasingly reported in prostate cancer (PCa) patients. However, despite growing numbers of PCa survivors and the well estimated negative impact of cognitive decline and emotional distress on survivors' quality of life, no study has assessed the whole range of cognitive and psychological sequelae as a response to treatment options for PCa. The objective of the present review was to systematically characterize the types and estimate the prevalence of the cognitive impairment and emotional burdens that were found in PCa survivors secondary to different treatment options.
Systematic, general reviews, meta-analysis, and overviews of review studies in English, that were published in PubMed during the last 10 years until l August 2019 and that reported psychological distress, anxiety, depression, cognitive decline, or dementia among individuals with PCa exposed to a particular treatment option were analyzed.
A total of 21 articles were reviewed. Some of the studies described one or more cognitive or psychological consequences of only one therapeutic strategy while others compared the psychological impacts among different strategies. Most of these studies suggested that either radical prostatectomy or active surveillance and radiotherapy were well-tolerated treatments in terms of psychological modifications. However, many of these patients may require additional emotional support. There is also increasing evidence that androgen deprivation therapy may be associated with depression, while controversy surrounding the association between cognitive dysfunction, dementia, and androgen deprivation therapy remains ambivalent.
Emotional distress and cognitive decline may accompany every PCa treatment option to different degrees. Accurate information on the short- and long-term effect of treatments on cognitive and psychological aspects should be provided to patients during treatment decision-making. There is also a need to develop well-targeted psychological and neurological interventions that could help those experiencing ongoing post-treatment difficulties.
前列腺癌(PCa)患者中,心理疾病以及认知障碍的报道日益增多。然而,尽管PCa幸存者数量不断增加,且认知衰退和情绪困扰对幸存者生活质量的负面影响已得到充分估计,但尚无研究评估作为PCa治疗选择反应的认知和心理后遗症的全貌。本综述的目的是系统地描述不同治疗选择导致的PCa幸存者中出现的认知障碍类型,并估计其患病率以及情绪负担情况。
分析过去10年直至2019年8月1日期间发表在PubMed上的英文系统综述、一般综述、荟萃分析以及综述研究概述,这些研究报告了接受特定治疗选择的PCa患者的心理困扰、焦虑、抑郁、认知衰退或痴呆情况。
共审查了21篇文章。一些研究仅描述了一种治疗策略的一种或多种认知或心理后果,而其他研究则比较了不同策略之间的心理影响。这些研究大多表明,就心理变化而言,根治性前列腺切除术或主动监测及放疗都是耐受性良好的治疗方法。然而,这些患者中的许多人可能需要额外的情感支持。越来越多的证据表明,雄激素剥夺疗法可能与抑郁症有关,而认知功能障碍、痴呆与雄激素剥夺疗法之间关联的争议仍不明确。
每种PCa治疗选择都可能在不同程度上伴随情绪困扰和认知衰退。在治疗决策过程中,应向患者提供有关治疗对认知和心理方面短期和长期影响的准确信息。还需要制定针对性强的心理和神经干预措施,以帮助那些在治疗后仍有持续困难的患者。